A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)

Trial Profile

A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Regorafenib (Primary) ; Imatinib
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Acronyms ALT GIST
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Feb 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 12 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top